Steven A Carr

US Patent:

20140045714, Feb 13, 2014

Filed:

Oct 26, 2011

Appl. No.:

13/881327

Inventors:

Robert Gerszten - Brookline MA, US
Michael Fifer - Brookline MA, US
Steven A. Carr - Boxford MA, US

International Classification:

G01N 33/68

US Classification:

506 9, 506 12, 435 792, 435 74, 435 611, 435 612, 4352872, 506 18

Abstract:

The invention provides methods for the early detection of cardiovascular injury using one or more cardiac injury biomarkers identified herein.

US Patent:

20220326241, Oct 13, 2022

Filed:

Aug 12, 2020

Appl. No.:

17/634218

Inventors:

- Houston TX, US
- Cambridge MA, US
- Boston MA, US
Steven Carr - Cambridge MA, US
Shankha Satpathy - Cambridge MA, US
Michael Gillette - Boston MA, US

International Classification:

G01N 33/574
C12Q 1/6886
G01N 33/68

Abstract:

Methods disclosed herein concern cancer proteogenomics, which integrates genomics, transcriptomics and mass spectrometry (MS)-based proteomics to gain insights into cancer biology and treatment efficacy. To promote clinical utility of embodiments herein, proteogenomics approaches were developed for frozen core needle biopsies using tissue-sparing specimen processing with or without a microscaled proteomics workflow.

US Patent:

20210406915, Dec 30, 2021

Filed:

Sep 8, 2021

Appl. No.:

17/468918

Inventors:

- Atlanta GA, US
Ellis L. Wong - Lexington MA, US
Steven R. Carr - San Jose CA, US

International Classification:

G06Q 30/00

Abstract:

In one example, a data package created by a particular wireless mobile device, and comprising metrics collected by the wireless mobile device, is retrieved. The metrics concern performance of the wireless mobile device in a wireless communication network, and are transformed into measures that enable derivation of a key performance indicator concerning the performance of the wireless mobile device. An enriched measure is generated by processing the measures based on correlations of wireless mobile device events in a time sequence, and the enriched measure is transformed into a KPI that is specific to the performance of the wireless mobile device. The KPI of the wireless mobile device is compared to a KPI of the population of wireless mobile devices, and results of the comparison of KPIs serve as a basis to resolve a problem regarding operation of the wireless mobile device.

US Patent:

20210382068, Dec 9, 2021

Filed:

Oct 2, 2019

Appl. No.:

17/280380

Inventors:

- Boston MA, US
- Cambridge MA, US
Karl Clauser - Cambridge MA, US
Steven Carr - Cambridge MA, US
Nir Hacohen - Boston MA, US
Catherine J. Wu - Boston MA, US

International Classification:

G01N 33/68
G01N 33/569
G16B 40/00
G16B 30/10
A61K 39/00

Abstract:

Adaptive immune responses rely on the ability of cytotoxic T cells to identify and eliminate cells displaying disease-specific antigens on human leukocyte antigen (HLA) class I molecules. Investigations into antigen processing and display have immense implications in human health, disease and therapy. To extend understanding of the rules governing antigen processing and presentation, immunopurified peptides from B cells, each expressing a single HLA class I allele, were profiled. A resource dataset containing thousands of peptides bound to distinct class I HLA-A, -B, and -C alleles was generated by implementing a novel allele-specific database search strategy. Applicants discovered new binding motifs, established the role of gene expression in peptide presentation and improved prediction of HLA-peptide binding by using these data to train machine-learning models. These streamlined experimental and analytic workflows enable direct identification and analysis of endogenously processed and presented antigens.

US Patent:

20190274292, Sep 12, 2019

Filed:

May 10, 2019

Appl. No.:

16/408792

Inventors:

- Cambridge MA, US
- Boston MA, US
STEVEN A. CARR - CAMBRIDGE MA, US
NAMRATA D. UDESHI - CAMBRIDGE MA, US
EMMA FINK - BOSTON MA, US

Assignee:

THE BROAD INSTITUTE, INC. - CAMBRIDGE MA
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - BOSTON MA

International Classification:

A01K 67/027
G01N 33/94
G01N 33/50
G01N 33/574
C12Q 1/6886
C12Q 1/6876

Abstract:

The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.

US Patent:

20190026748, Jan 24, 2019

Filed:

Sep 26, 2018

Appl. No.:

16/143333

Inventors:

- Sunnyvale CA, US
Ellis L. Wong - Lexington MA, US
Steven R. Carr - San Jose CA, US

International Classification:

G06Q 30/00

Abstract:

In one example, a data package created by a particular wireless mobile device, and comprising metrics collected by the wireless mobile device, is retrieved. The metrics concern performance of the wireless mobile device in a wireless communication network, and are transformed into measures that enable derivation of a key performance indicator concerning the performance of the wireless mobile device. An enriched measure is generated by processing the measures based on correlations of wireless mobile device events in a time sequence, and the enriched measure is transformed into a KPI that is specific to the performance of the wireless mobile device. The KPI of the wireless mobile device is compared to a KPI of the population of wireless mobile devices, and results of the comparison of KPIs serve as a basis to resolve a problem regarding operation of the wireless mobile device.

US Patent:

20170343553, Nov 30, 2017

Filed:

Sep 22, 2016

Appl. No.:

15/272870

Inventors:

- Cambridge MA, US
- Boston MA, US
Steven A. Carr - Boxford MA, US
Kenneth Tanabe - Brookline MA, US

Assignee:

Massachusetts Institute of Technology - Cambridge MA
The General Hospital Corporation d/b/a Massachusettes General Hospital - Boston MA
The Broad Institute, Inc. - Cambridge MA

International Classification:

G01N 33/574
A61K 49/00
A61K 47/68
A61K 51/10

Abstract:

Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.

US Patent:

20160338326, Nov 24, 2016

Filed:

Mar 18, 2016

Appl. No.:

15/074920

Inventors:

- Cambridge MA, US
- Boston MA, US
STEVEN A. CARR - CAMBRIDGE MA, US
NAMRATA D. UDESHI - CAMBRIDGE MA, US
EMMA FINK - BOSTON MA, US

Assignee:

THE BROAD INSTITUTE, INC. - CAMBRIDGE MA
THE BRIGHAM AND WOMEN'S HOSPITAL, INC. - BOSTON MA

International Classification:

A01K 67/027
C12Q 1/68
G01N 33/50

Abstract:

The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.